Valuation: Synlogic, Inc.

Market Cap 12.98M 11.6M 10.81M 9.8M 18.45M 1.23B 18.59M 130M 50.7M 641M 48.76M 47.69M 2.06B P/E 2024
-0.73x
P/E 2025 -13.7x
Enterprise Value -1.68M -1.5M -1.4M -1.27M -2.39M -160M -2.41M -16.8M -6.58M -83.14M -6.32M -6.19M -267M EV / Sales 2024
-311x
EV / Sales 2025 -
Free-Float
82.45%
Yield 2024 *
-
Yield 2025 -
1 day-0.93%
1 week-0.93%
Current month-5.36%
1 month-13.11%
3 months+49.09%
6 months+70.97%
Current year-5.36%
1 week 1.06
Extreme 1.06
1.1
1 month 1.06
Extreme 1.06
1.19
Current year 0.54
Extreme 0.5401
1.3
1 year 0.54
Extreme 0.5401
1.87
3 years 0.54
Extreme 0.5401
5.12
5 years 0.54
Extreme 0.5401
45
10 years 0.54
Extreme 0.5401
345
Manager TitleAgeSince
Chief Executive Officer 45 31/12/2024
Director TitleAgeSince
Director/Board Member 74 27/08/2017
Chairman 74 27/08/2017
Director/Board Member 66 30/09/2012
Date Insider Type Main position Quantity % Market Cap. Importance
27/07/26
NEA Management Co. LLC
Tax optionCompany -5,281,690 45.1556%
29/10/25 Sell

Chief Executive Officer

157 0.0013%
26/04/25 Free

Director

15,000 0.1282%
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%-0.93%-31.61%-56.56% 12.98M
-0.32%-5.97%+57.78%+74.48% 70.44B
+0.83%-13.55%+5.50%+54.26% 50.31B
+2.97%+0.69%+11.04%+36.40% 47.51B
-0.58%+0.27%+27.93%+30.76% 42.91B
-2.84%-5.72%+286.54%+530.02% 40.39B
-0.38%-3.78%+6.74%+95.25% 39.69B
-0.39%-1.48%+10.41%+43.19% 30.59B
-2.95%-12.28%+43.51%+1.51% 26.8B
-7.13%-7.02%-12.99%-14.07% 22.36B
Average -1.17%-5.17%+40.48%+79.52% 37.1B
Weighted average by Cap. -0.65%-5.61%+51.49%+100.43%

Financials

2024 2025
Net sales 8K 7.15K 6.66K 6.04K 11.37K 759K 11.45K 79.8K 31.24K 395K 30.04K 29.39K 1.27M -
Net income -23.36M -20.87M -19.45M -17.63M -33.18M -2.22B -33.45M -233M -91.21M -1.15B -87.73M -85.8M -3.7B -1M -898K -837K -759K -1.43M -95.4M -1.44M -10.02M -3.92M -49.61M -3.77M -3.69M -159M
Net Debt -18.86M -16.85M -15.7M -14.24M -26.79M -1.79B -27M -188M -73.64M -931M -70.83M -69.28M -2.99B -14.67M -13.1M -12.21M -11.07M -20.84M -1.39B -21M -146M -57.27M -724M -55.09M -53.88M -2.32B
Projected Income Statement - Annual - Synlogic, Inc.
Logo Synlogic, Inc.
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Employees
1
Date Price Change Volume
13/10/26 US$1.060 -0.93% 11,009
12/10/26 US$1.070 -2.73% 2,382
08/10/26 US$1.100 0.00% 73,886
07/10/26 US$1.100 +2.80% 59,378
06/10/26 US$1.070 -2.73% 134,200

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Synlogic, Inc.
  1. Stock Market
  2. Stocks
  3. SYBX Stock